ECRIN Integrating Activity

Funding programme: Horizon 2020 (N 284395)


Budget: €11M

Duration: 5 years (January 2012 to December 2017)

ECRIN Integrating Activity (ECRIN-IA) is a collaborative project, initially running from 2012 to the end of 2015, funded by the European Commission Framework Program 7 and involving 23 countries (click here for country contacts). Work package (WP) 7 was extended until 2017.

ECRIN-IA’s purpose is to build a consistent organisation for clinical research in Europe, providing generic tools and services to multinational studies, and supporting the construction of pan-European disease-oriented networks that will become ECRIN users and provide clinical research projects. This organisation will improve Europe’s attractiveness to industry, boost its scientific competitiveness, and result in better healthcare for European citizens. Activities are divided into nine work packages (WPs):

  • WP1–Management, governance and coordination of the project
    Overall management of the project is coordinated by the ECRIN Paris office.
  • WP2–Expansion, capacity building and funding
    Networking activities promote pan-European expansion, capacity building and partnership with other world regions, and promote appropriate funding mechanisms.
  • WP3–Education, e-services and communication
    E-services for researchers and education material to train professionals and patients associations are developed in this work package, which also addresses communication with users, patients, citizens and policymakers.
  • WP4, 5 & 6–structuring rare disease, medical device and nutrition networks
    Structuring European hubs and networks for clinical research on rare diseases (WP4), medical devices (WP5) and nutrition (WP6). The networks will design and conduct multinational clinical studies.
  • WP7–Transnational access
    Transnational access activities support the cost of multinational extension of clinical trials selected by the ECRIN Scientific Board. Five trials are supported in three areas: MENAC (nutrition); ESCALE and POEM vs LHM (medical devices), RESCUE ESES and IMPACTT (rare diseases).  
  • WP8–Monitoring
    Identification, assessment and validation of tools for the implementation of risk-based monitoring strategies will improve the efficiency of ECRIN services.
  • WP9–Data management
    Adaptation of the VISTA Trials data management software will provide a state-of-the-art and efficient Clinical Data Management Tool for multinational clinical trials to the ECRIN user community and for non-commercial clinical research.